Tivdak

Chemical Nametisotumab vedotin-tftv
Dosage FormLyophilized powder (intravenous; 40 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanySeagen
Approval Year2021

Indication

  • For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Last updated on 4/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivdak (tisotumab vedotin-tftv) Prescribing Information.2021Seagen Inc., Bothell, WA